Mankind Pharma Signs Agreement with Takeda
The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark.
Mumbai: Mankind Pharma Limited and Takeda Pharmaceutical Company Limited signed a Non-Exclusive Patent License Agreement for commercialising 'Vonoprazan' in the Indian market. The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark.
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders, including Gastroesophageal Reflux Disease (GERD). The drug is effective in treating conditions such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis, and Helicobacter pylori eradication.
Mr. M Ramesh, EVP – Global Business Development - Mankind Pharma Limited, said, “This non-exclusive patent license agreement with Takeda aligns with our commitment to bringing innovative and effective treatments to patients in India. By introducing Vonoprazan, we aim to address a significant medical need and improve the quality of life for those suffering from acid-related illnesses with a new and advanced option for managing acid-related disorders, potentially offering improved health outcomes and quality of life.”
Read Also : Mukesh Singh Verma gives his resignation as CCO and Principal Officer of Utkarsh Small Finance BankAbout Mankind Pharma
About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 30 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 660 scientists.
News Must Read
- Mukesh Singh Verma gives his resignation as CCO and Principal Officer of Utkarsh Small Finance Bank
- Mahesh Kumar Sharma Recommended as Director (Finance) for NHPC Limited
- Coal India Dividend FY26: PSU to consider financial results and interim dividend soon, Check now
- Bank of Maharashtra Q1FY26: Net Profit rises 23.14%, Gross NPA improves marginally
- Om Prakash Sinha takes charge as Director (Exploration) of ONGC
- BPCL disclosed Changes in Senior Management of Board
- Kamesh Kasana joins Bharat Electronics Ltd as Director
- PSU Price Target: RVNL bags major contract from DMRC, stock revives with marginal gain
- Saumitra Priya Srivastava Selected as Director Marketing at IOCL
- Captain (IN) P. Sunilkumar (Retd.) takes over as Director Corporate Planning & Personnel of GRSE